MRS as an Aid to Diagnose Malignant Transformation in Low-Grade Gliomas with Increasing Contrast Enhancement

References

1. 1.↵
   2. Ostrom QT,
   3. Cioffi G,
   4. Gittleman H, et al

   . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol 2019;21:v1–100 doi:10.1093/neuonc/noz150 pmid:31675094

   CrossRefPubMed
2. 2.↵
   2. van den Bent MJ,
   3. Wefel JS,
   4. Schiff D, et al

   . Response Assessment in Neuro-Oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011;12:583–93 doi:10.1016/S1470-2045(11)70057-2

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Narang AK,
   3. Chaichana KL,
   4. Weingart JD, et al

   . Progressive low-grade glioma: assessment of prognostic importance of histologic reassessment and MRI findings. World Neurosurg 2017;99:751–57 doi:10.1016/j.wneu.2016.04.030 pmid:27108796

   CrossRefPubMed
4. 4.↵
   2. Fink JR,
   3. Carr RB,
   4. Matsusue E, et al

   . Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects. J Magn Reson Imaging 2012;35:56–63 doi:10.1002/jmri.22801 pmid:22002882

   CrossRefPubMed
5. 5.↵
   2. Matsusue E,
   3. Fink JR,
   4. Rockhill JK, et al

   . Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 2010;52:297–306 doi:10.1007/s00234-009-0613-9 pmid:19834699

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Schiff D,
   3. van den Bent M,
   4. Vogelbaum MA, et al

   . Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus. Neuro Oncol 2019;21:837–53 doi:10.1093/neuonc/noz033 pmid:30753579

   CrossRefPubMed
7. 7.↵
   2. Bertholdo D,
   3. Watcharakorn A,
   4. Castillo M

   . Brain proton magnetic resonance spectroscopy: introduction and overview. Neuroimaging Clin N Am 2013;23:359–80 doi:10.1016/j.nic.2012.10.002 pmid:23928194

   CrossRefPubMed
8. 8.↵
   2. Oz G,
   3. Alger JR,
   4. Barker PB, et al

   ; MRS Consensus Group. Clinical proton MR spectroscopy in central nervous system disorders. Radiology 2014;270:658–79 doi:10.1148/radiol.13130531 pmid:24568703

   CrossRefPubMed
9. 9.↵
   2. Hattingen E,
   3. Raab P,
   4. Franz K, et al

   . Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology 2008;50:759–67 doi:10.1007/s00234-008-0409-3 pmid:18523762

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Bourdillon P,
    3. Hlaihel C,
    4. Guyotat J, et al

    . Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status. J Neurooncol 2015;122:529–37 doi:10.1007/s11060-015-1737-x pmid:25716744

    CrossRefPubMed
11. 11.↵
    2. Jalbert LE,
    3. Neill E,
    4. Phillips JJ, et al

    . Magnetic resonance analysis of malignant transformation in recurrent glioma. Neuro Oncol 2016;18:1169–79 doi:10.1093/neuonc/now008 pmid:26911151

    CrossRefPubMed
12. 12.↵
    2. Neill E,
    3. Luks T,
    4. Dayal M, et al

    . Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. J Neurooncol 2017;132:171–79 doi:10.1007/s11060-016-2355-y pmid:28124178

    CrossRefPubMed
13. 13.↵
    2. Alimenti A,
    3. Delavelle J,
    4. Lazeyras F, et al

    . Monovoxel 1H magnetic resonance spectroscopy in the progression of gliomas. Eur Neurol 2007;58:198–209 doi:10.1159/000107940 pmid:17823533

    CrossRefPubMed
14. 14.↵
    2. Tedeschi G,
    3. Lundbom N,
    4. Raman R, et al

    . Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997;87:516–24 doi:10.3171/jns.1997.87.4.0516 pmid:9322842

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Bobek-Billewicz B,
    3. Stasik-Pres G,
    4. Hebda A, et al

    . Anaplastic transformation of low-grade gliomas (WHO II) on magnetic resonance imaging. Folia Neuropathol 2014;52:128–40 doi:10.5114/fn.2014.43784 pmid:25118898

    CrossRefPubMed
16. 16.↵
    2. Murphy ES,
    3. Leyrer CM,
    4. Parsons M, et al

    . Risk factors for malignant transformation of low-grade glioma. Int J Radiat Oncol Biol Phys 2018;100:965–71 doi:10.1016/j.ijrobp.2017.12.258 pmid:29485076

    CrossRefPubMed
17. 17.↵
    2. Tom MC,
    3. Park DYJ,
    4. Yang K, et al

    . Malignant transformation of molecularly classified adult low-grade glioma. Int J Radiat Oncol Biol Phys 2019;105:1106–12 doi:10.1016/j.ijrobp.2019.08.025 pmid:31461674

    CrossRefPubMed
18. 18.↵
    2. Chaichana KL,
    3. McGirt MJ,
    4. Laterra J, et al

    . Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 2010;112:10–17 doi:10.3171/2008.10.JNS08608 pmid:19361270

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Soffietti R,
    3. Baumert BG,
    4. Bello L, et al

    ; European Federation of Neurological Societies. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 2010;17:1124–33 doi:10.1111/j.1468-1331.2010.03151.x pmid:20718851

    CrossRefPubMed
20. 20.↵
    2. Sepulveda-Sanchez JM,
    3. Muñoz Langa J,
    4. Arráez MÁ, et al

    . SEOM clinical guideline of diagnosis and management of low-grade glioma. Clin Transl Oncol 2018 2017;20:3–15 doi:10.1007/s12094-017-1790-3 pmid:29124520

    CrossRefPubMed
21. 21.↵
    2. Castillo M,
    3. Smith JK,
    4. Kwock L

    . Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol 2000;21:1645–49

    Abstract/FREE Full Text